Joan Cheng1, Angela Cheng1, Bethan L Clifford2, Xiaohui Wu2, Ulf Hedin3, Lars Maegdefessel4,5, Nathalie Pamir6, Tamer Sallam2,7, Elizabeth J Tarling2,7,8, Thomas Q de Aguiar Vallim1,2,7,8. 1. From the Department of Biological Chemistry (J.C., A.C., T.Q.d.A.V.), University of California Los Angeles. 2. Department of Medicine (B.L.C., X.W., T.S., E.J.T., T.Q.d.A.V.), University of California Los Angeles. 3. Department of Molecular Medicine and Surgery (U.H.), Karolinska Institute, Solna, Sweden. 4. Department of Medicine (L.M.), Karolinska Institute, Solna, Sweden. 5. Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar-Technical University Munich, Germany (L.M.). 6. Department of Medicine, Knight Cardiovascular Institute, Oregon Health & Sciences University, Portland (N.P.). 7. Molecular Biology Institute (T.S., E.J.T., T.Q.d.A.V.), University of California Los Angeles. 8. Johnsson Comprehensive Cancer Center (E.J.T., T.Q.d.A.V.), University of California Los Angeles.
Abstract
OBJECTIVE: Atherosclerosis is a leading cause of death in developed countries. MicroRNAs act as fine-tuners of gene expression and have been shown to have important roles in the pathophysiology and progression of atherosclerosis. We, and others, previously demonstrated that microRNA-144 (miR-144) functions to post-transcriptionally regulate ABCA1 (ATP binding cassette transporter A1) and plasma HDL (high-density lipoprotein) cholesterol levels. Here, we explore how miR-144 inhibition may protect against atherosclerosis. Approach and Results: We demonstrate that miR-144 silencing reduced atherosclerosis in male, but not female low-density lipoprotein receptor null (Ldlr-/-) mice. MiR-144 antagonism increased circulating HDL cholesterol levels, remodeled the HDL particle, and enhanced reverse cholesterol transport. Notably, the effects on HDL and reverse cholesterol transport were more pronounced in male mice suggesting sex-specific differences may contribute to the effects of silencing miR-144 on atherosclerosis. As a molecular mechanism, we identify the oxysterol metabolizing enzyme CYP7B1 (cytochrome P450 enzyme 7B1) as a miR-144 regulated gene in male, but not female mice. Consistent with miR-144-dependent changes in CYP7B1 activity, we show decreased levels of 27-hydroxycholesterol, a known proatherogenic sterol and the endogenous substrate for CYP7B1 in male, but not female mice. CONCLUSIONS: Our data demonstrate silencing miR-144 has sex-specific effects and that treatment with antisense oligonucleotides to target miR-144 might result in enhancements in reverse cholesterol transport and oxysterol metabolism in patients with cardiovascular disease.
OBJECTIVE: Atherosclerosis is a leading cause of death in developed countries. MicroRNAs act as fine-tuners of gene expression and have been shown to have important roles in the pathophysiology and progression of atherosclerosis. We, and others, previously demonstrated that microRNA-144 (miR-144) functions to post-transcriptionally regulate ABCA1 (ATP binding cassette transporter A1) and plasma HDL (high-density lipoprotein) cholesterol levels. Here, we explore how miR-144 inhibition may protect against atherosclerosis. Approach and Results: We demonstrate that miR-144 silencing reduced atherosclerosis in male, but not female low-density lipoprotein receptor null (Ldlr-/-) mice. MiR-144 antagonism increased circulating HDL cholesterol levels, remodeled the HDL particle, and enhanced reverse cholesterol transport. Notably, the effects on HDL and reverse cholesterol transport were more pronounced in male mice suggesting sex-specific differences may contribute to the effects of silencing miR-144 on atherosclerosis. As a molecular mechanism, we identify the oxysterol metabolizing enzyme CYP7B1 (cytochrome P450 enzyme 7B1) as a miR-144 regulated gene in male, but not female mice. Consistent with miR-144-dependent changes in CYP7B1 activity, we show decreased levels of 27-hydroxycholesterol, a known proatherogenic sterol and the endogenous substrate for CYP7B1 in male, but not female mice. CONCLUSIONS: Our data demonstrate silencing miR-144 has sex-specific effects and that treatment with antisense oligonucleotides to target miR-144 might result in enhancements in reverse cholesterol transport and oxysterol metabolism in patients with cardiovascular disease.
Authors: Ji-Young Lee; Jenelle M Timmins; Anny Mulya; Thomas L Smith; Yiwen Zhu; Edward M Rubin; Jeffrey W Chisholm; Perry L Colvin; John S Parks Journal: J Lipid Res Date: 2005-07-16 Impact factor: 5.922
Authors: Michihisa Umetani; Hideharu Domoto; Andrew K Gormley; Ivan S Yuhanna; Carolyn L Cummins; Norman B Javitt; Kenneth S Korach; Philip W Shaul; David J Mangelsdorf Journal: Nat Med Date: 2007-09-16 Impact factor: 53.440
Authors: Daniel P Zalewski; Karol P Ruszel; Andrzej Stępniewski; Dariusz Gałkowski; Marcin Feldo; Janusz Kocki; Anna Bogucka-Kocka Journal: J Clin Med Date: 2022-03-15 Impact factor: 4.241